Innovent Biologics, Inc., a biopharmaceutical company, and AnHeart Therapeutics Co., Ltd. have jointly announced interim clinical data from a Phase 2 trial (TRUST) evaluating Taletrectinib (AB-106), an investigational next-generation ROS1/NTRK inhibitor in ROS1-positive NSCLC (non-small cell lung cancer).

The results were presented as a keynote on September 25^th-29^th, 2021, at the Chinese Society of Clinical Oncology (CSCO) 2021 Annual Meeting.

According to sources close to the trial, taletrectinib was well tolerated with treatment-related adverse events being gastrointestinal side effects, reversible aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels rising.

Dr. Caicun Zhou, Director of the Department of Oncology in Shanghai Pulmonary Hospital, stated that they are delighted by the interim Phase 2 results, which suggest that taletrectinib is a safe and acceptable new treatment for patients with ROS1 fusion-positive lung cancer.

Responses appear to be more spectacular in crizotinib treatment-naive patients. While the number of crizotinib pre-treated patients is small, most patients appear to be benefiting from the medication so far.

As per Dr. Hui Zhou, Senior VP, Innovent, said that their firm is pleased to see the interim Phase 2 data of taletrectinib to be presented at the CSCO event.

ROS1-positive patients currently have limited treatment options in China, claims Dr. Zhou. New therapies are needed urgently, and taletrectinib has good safety and efficacy results, which offers good treatment chances to patients with ROS1 fusion-positive NSCLC.

Bing Yan, MD, Chief Medical Officer and Co-founder of AnHeart Therapeutics, claims that their team is focused on finalizing patient enrollment for its Phase 2 TRUST trial.

The interim data builds a strong foundation for its ongoing taletrectinib clinical trial. AnHeart sincerely express gratitude towards the patients, families and investigators in the TRUST trial and are looking forward to advancing new development in taletrectinib.

Source Credit - https://www.prnewswire.com/news-releases/innovent-and-anheart-announce-interim-data-from-phase-2-trial-of-taletrectinib-in-ros1-positive-nsclc-at-the-csco-2021-annual-meeting-301385147.html